- Presentation available on NRx Pharmaceuticals website at
https://www.nrxpharma.com/hope-therapeutics/
KEY UPDATES ARE AS FOLLOWS:
- NRx management is proposing to award 50% of founding shares
in HOPE Therapeutics to current shareholders together with a
royalty coupon with an expected ex-dividend date in the near
future, all subject to board approval
- Dividend to be available to all shareholders who sign a
covenant not to engage in short sales of NRx stock, subject to
board approval
- HOPE anticipates having manufactured ketamine supplies for
shipment under 503a pharmacy regulations by July 1, 2024
RADNOR,
Pa., Feb. 26, 2024 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals," the
"Company"), a clinical-stage biopharmaceutical company, today
announced that Dr. Jonathan Javitt,
Chairman and Chief Scientist of NRx Pharmaceuticals, will present a
corporate overview at the BIO CEO & Investor Conference, which
is scheduled to take place February 26-27,
2024, at the Marriott Marquis in New York City. Presenting with him will be
Matthew Duffy, the newly-appointed
co-CEO of HOPE Therapeutics. The presentation will be available on
the NRx Pharmaceuticals website at
https://www.nrxpharma.com/hope-therapeutics/.
"Subsequent to our announcement last week, we are in the process
of completing a Memorandum of Understanding that may enable us to
begin sales of IV ketamine to qualified clinics in partnership with
a holder of a nationwide pharmacy license. Additionally, we will be
updating investors with regard to our plans to add a digital
therapeutic component to our ketamine offering that has potential
to extend the clinical benefit to patients." said Dr. Javitt. "We
thank our investors for their support and look forward to updating
the public on our progress towards building a lifesaving
therapy."
Presentation Date: Monday, February 26th, 2024
Time: 2:30 PM ET
Location: The Royale Room, Marriot Marquis, New York City
Registration: https://bcic.bio.org/registration
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx has partnered with Alvogen and Lotus around the
development and marketing of NRX-101 for the treatment of suicidal
bipolar depression. NRX-101 additionally has potential to act as a
non-opioid treatment for chronic pain, as well as a treatment for
complicated UTI.
NRx has recently announced plans to submit a New Drug
Application for HTX-100 (IV ketamine), through Hope Therapeutics,
in the treatment of suicidal depression, based on results of
well-controlled clinical trials conducted under the auspices of the
US National Institutes of Health and newly obtained data from
French health authorities, licensed under a data sharing agreement.
NRx was awarded Fast Track Designation for development of ketamine
(NRX-100) by the US FDA as part of a protocol to treat patients
with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a
wholly-owned subsidiary of NRX Pharmaceuticals focused on
development and marketing of an FDA-approved form of intravenous
ketamine for the treatment of acute suicidality and depression
together with a digital therapeutic-enabled platform designed to
augment and preserve the clinical benefit of NMDA-targeted drug
therapy.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-launches-hope-therapeutics-inc-at-the-bio-ceo--investor-conference-2024-302070687.html
SOURCE NRx Pharmaceuticals, Inc.